Catalogue

Background
CYP3A genes encode monooxygenases, enzymes which catalyze drug metabolism and the synthesis of cholesterol, steroids and other lipids. CYP3A (cytochrome P450, family 3, subfamily A), the most abundant P450 enzyme in human liver, is responsible for the metabolism of more than 50% of all clinical drugs. CYP3A members localize in organs that associate with drug disposition, including the liver, gastrointestinal tract and kidney. The CYP3A cluster consists of four genes: CYP3A43, CYP3A4, CYP3A7 and CYP3A5, and two pseudogenes: CYP3A5P1 and CYP3A5P2. The CYP3A cluster maps to gene locus 7q21.3-q22.1.

Synonyms: CYP3A7; CYP450 3A7 (EC 1.14.14.1), CYPIIIA7, P450-HFLA

Source

Immunogen: Hybridoma produced by the fusion of splenocytes from BALB/c mice immunized with a synthetic peptide derived from the C-terminus of the human CYP3A7 protein and mouse myeloma Ag8563 cells.

Product

Product Form: Unconjugated

Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide

Purification Method: Protein A/G Chromatography

Concentration: See vial for concentration

Applications
Antibody can be used for Western blotting (1-2 µg/ml) and immunohistochemistry on formalin-fixed, paraffin-embedded tissue sections (1-5 µg/ml). When used in conjunction with CYP3A5 (Cat. No. X2047M), can differentiate between the CYP3A family members, 3A5 and 3A7. Optimal concentration should be evaluated by serial dilutions.

Functional Analysis: Western Blotting

Positive Control: Prostate cancer

Storage
Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

Product Stability: See expiration date on vial

Shipping Conditions: Ship at ambient temperature, freeze upon arrival

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Nordic-MUbio​ accepts no liability for any inaccuracies or omissions in this information.

References
1. Kumarakasingham, M., et al. (2005). Cytochrome p450 profile of colorectal cancer: Identification of markers of prognosis. Clin. Cancer Res. 11(10);3758-3765. 2. Leeder, J.S., et al. (2005). Variability of CYP3A7 expression in human fetal liver. J. Pharmacol. Exp. Ther. 314(2);626-635. 3. Ogino, M., et al. (2002). Selective suppressions of human CYP3A forms, CYP3A5 and CYP3A7, by troglitazone in HepG2 cells. 17(1);42-46.

Protein Reference(s)

Database Name: UniProt

Accession Number: Q9H241

Species Accession: Human

Safety Datasheet(s) for this product: